value

A Phase 2/3 readout for $IDYA’s lead asset darovasertib in uveal melanoma, a rare form of eye cancer is upcoming. If results are positive, $IDYA could move quickly toward filing for FDA approval. Comparing darovasertib to Kimmtrak, the only FDA-approved drug for the indication, @soowannaway (Graig Suvannavejh) says: “The limitation of Kimmtrak is that for the type of therapy that it is, the TCR based therapeutics, it is restricted by HLA status. And so, this is not a drug that would be amenable to all patients with uveal melanoma, and therein lies a potential opportunity for other companies.” #BiotechHangout

At #AAD2026, Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discussed emerging long-term data presented for #sonelokimab, an investigational nanobody from MoonLake Immunotherapeutics, for the treatment of moderate to severe HS. hubs.li/Q048LsJb0

🇨🇳 Legend Biotech $LEGN, a joint venture of GenScript Biotech, is reportedly planning a Hong Kong listing as early as this year, aiming to raise US$300–400M, according to IFR. Founded in 2014, Legend Biotech describes itself as the world’s largest standalone cell therapy company, with a growing global footprint in CAR‑T and cell‑based therapies. #Biotech #CellTherapy #CAR_T #HongKongIPO #ChinaBiotech #CapitalMarkets